Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.41 |
| ▸ | PREP | P48147 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980653 | 0.82 | PREP (0.42) | SLC2A1PREPALDH1A1LMNAHTT | |
| SCHEMBL19895108 | 0.80 | BACE1 (0.37) | SLC2A1ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL10827924 | 0.79 | PREP (0.42) | PREPCA12CA1CA9 | |
| SCHEMBL8379284 | 0.79 | PREP (0.40) | SLC2A1PREPALDH1A1LMNAHTT | |
| SCHEMBL8906116 | 0.79 | CA1 (0.56) | PREPALDH1A1LMNACA12CA1 | |
| SCHEMBL18082660 | 0.78 | PLK1 (0.56) | SLC2A1ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL31270922 | 0.77 | HPGD (0.58) | PREPHTTSMN1; SMN2PLK1MAPT | |
| SCHEMBL8382753 | 0.77 | TRPA1 (0.44) | SLC2A1PREPALDH1A1LMNAHTT | |
| SCHEMBL2500559 | 0.76 | ELANE (0.52) | PREPLMNACA12CA1CA9 | |
| SCHEMBL8699124 | 0.76 | MAPT (0.40) | PREPALDH1A1LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254241-A1 | Enzyme inhibitor; cognition activators | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1431280-A1 | ARYL SULFAMATE DERIVATIVES | Kyowa Hakko Kogyo Co., Ltd (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254241-A1 | Enzyme inhibitor; cognition activators | SULT1A1, STS, CYP26A1 | SLC2A1 3900/4885PREP 545/4885ALDH1A1 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.